Drugs / anti-CD19 redirected NK cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01974479 | Sep 2013 → Feb 2017 | B-cell acute lymphoblastic leukemia | National University Health System, Singapore | Suspended | No outcome recorded Stop: Business |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | anti-CD19 redirected NK cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01974479 ↗ |
| Action | Deplete | “markedly enhanced NK cell-mediated killing of leukemic cells” NCT01974479 ↗ |
| Modality | Cell therapy | “expanded, activated redirected NK cells” NCT01974479 ↗ |
| Route | Intravenous | “Intravenous Infusion of activated NK cells bearing anti-CD19-BB-zeta receptors” NCT01974479 ↗ |
| Target | CD19 | “chimeric receptors directed against CD19” NCT01974479 ↗ |